Get started

Davita

DaVita (DVA) AnalysisLeading Dialysis Service Provider: DaVita NYSE:DVA stands as a top kidney dialysis service provider in the U.S., demonstrating strong resilience post-COVID-19. CEO Javier Rodriguez emphasized the company's strengthened position and continued investments in staff and systems. Expansive Market Potential: With 40 million Americans affected by kidney disease, the dialysis market is valued at an impressive $100 billion. DaVita, as a major player, serves a significant portion of the 786,000 people requiring dialysis or transplants annually. Financial Performance: DaVita boasts a robust financial performance with a remarkable 53% Return on Equity (ROE) over the past five years, indicating effective value creation and investor capital management. Investment Outlook: Bullish Outlook: We are bullish on DVA above the $125.00-$126.00 range. Upside Potential: With a target set at $195.00-$200.00, DaVita’s strong market position and impressive financial metrics suggest strong growth potential in this essential healthcare sector. 📊🩺 Stay tuned for promising investment opportunities with DaVita! #DVA #HealthcareServices 📈🔍
NYSE:DVALong
by Richtv_official
DaVita (DVA) Stock Spike on Hope for Chronic Kidney Disease CureDaVita ( NYSE:DVA ) stock witnessed a significant surge as Novo Nordisk (NVO) unveiled promising results from its weight-loss drug study, offering newfound hope for patients battling chronic kidney disease. The groundbreaking findings have ignited investor optimism and reshaped the landscape for dialysis companies like DaVita and Fresenius Medical Care (FMS). Novo Nordisk's Study Breakthrough: Novo Nordisk's study, known as Flow, demonstrated that a weekly dose of semaglutide, the weight-loss drug, substantially reduced the risk of death for chronic kidney disease patients by an impressive 24%. This revelation dispels concerns that weight-loss drugs might diminish the need for dialysis machines, reaffirming the critical role of companies like DaVita in kidney disease treatment. Market Reaction and Stock Performance: The announcement sent shockwaves through the market, propelling DaVita stock up by 7.1% to 134.65, while shares of rival dialysis company Fresenius Medical Care (FMS) also surged by 11.2%. Despite Novo Nordisk's stock dipping by 2.6%, the implications of the study have set a positive tone for the future of kidney disease treatment. Semaglutide's Potential Approval: With the encouraging results from the Flow study, Novo Nordisk is poised to seek FDA approval for semaglutide as a treatment for type 2 diabetes and chronic kidney disease. If approved, semaglutide would mark a groundbreaking advancement, potentially becoming the first drug in its class to gain approval for this purpose. Market Outlook and Future Prospects: The positive momentum in DaVita stock signals an extension of its breakout trajectory, with shares approaching record highs achieved in mid-2021. Novo Nordisk's executive vice president for development, Martin Holst Lange, expressed excitement about semaglutide's potential to revolutionize kidney disease treatment, particularly for the significant percentage of type 2 diabetes patients grappling with chronic kidney disease. Competition and Industry Dynamics: As Novo Nordisk vies for FDA approval, its chief rival, Eli Lilly (LLY), remains a formidable competitor with its drug tirzepatide. The evolving dynamics in the pharmaceutical landscape underscore the fierce competition and relentless pursuit of innovation in the quest to address the unmet needs of patients with chronic conditions. Conclusion: In conclusion, Novo Nordisk's groundbreaking study represents a pivotal moment in the fight against chronic kidney disease, offering renewed hope and optimism for patients and investors alike. With DaVita and Fresenius poised to play a central role in delivering care to those in need, the future holds promising prospects for advancements in kidney disease treatment and improved outcomes for patients worldwide.
NYSE:DVALong
by DEXWireNews
DaVitaCorporate Profile DaVita is a Fortune 500® health care provider focused on transforming care delivery to improve quality of life for patients around the globe. The company is the largest provider of kidney care services in the U.S. and has been a leader in clinical quality and innovation for 20 years. Through DaVita Kidney Care, the company treats patients with chronic kidney failure and end stage renal disease. DaVita is committed to bold, patient-centric care models, implementing the latest technologies and moving toward integrated care offerings for all. As of June 30, 2020, DaVita served 205,000 patients at 2,795 outpatient dialysis centers in the United States. The company also operated 287 outpatient dialysis centers in ten countries across the world. DaVita has reduced hospitalizations, improved mortality, and worked collaboratively to propel the kidney care industry to adopt an equitable and high-quality standard of care for all patients, everywhere. There are like 5 of these within every mile in Chicago lol It's inevitable lol *not investing advice Today, DaVita Kidney Care announced that more than 100,000 DaVita patients have received a kidney transplant since 2000. This milestone represents the culmination of two decades of innovative strategies spearheaded by the kidney care provider to increase patient education and access to kidney transplantation. DaVita Kidney Care (PRNewsfoto/DaVita Kidney Care) "We are deeply committed to helping every interested patient be evaluated by transplant centers and stay transplant ready," said Dr. Jeff Giullian, chief medical officer for DaVita. "Transplant is the best option for most patients with kidney failure, as it's the only way for these patients to live without relying on dialysis." According to the United Network for Organ Sharing (UNOS), 24,273 people received a kidney transplant in the United States in 2019. More than 6,000 DaVita patients have already received a transplant in 2020, despite the many setbacks transplant programs faced due to COVID-19. At the same time, nearly 100,000 people in the United States remain on a kidney transplant waitlist. The average wait for a non-living kidney donor match is 3.6 years. The Advancing American Kidney Health initiative launched in 2019 calls for doubling the number of kidneys available for transplant by 2030. The initiative lays out a roadmap to help organ procurement organizations and transplant centers reach this goal, which aligns with DaVita's longstanding work to empower all patients to choose to be evaluated for transplant. My name is Ski Mask and I've been making bad decision all my life. Strike Price: $109.35 Like Follow Agree Disagree! What do you think?
NYSE:DVALong
by Redimere_91
Davita - now a BULL trend Technicals analysis WEEKLY Davita broke a downtrend channel, and is now in a consolidation above the 200SMA. (Bull) 50SMA is now crossing above the 200SMA. (Bull) OBV and RSI show divergence, as they have moved in oposite directions since early August. (Short). However... on a daily chart , we see a decent uptrend since early June. Headlines / Fundamental On July 10th: President Donald Trump on Wednesday signed an executive order reimbursing for kidney transplants and reducing the reliance on the costly treatments at dialysis clinics. Analyst fair value target price is $79. Meaning 38% undervalued .
NYSE:DVALong
by dorfmanmaster